Adverse events associated with MMR vaccines in Japan

Pediatrics International

Volumn 38, Issue 3, 1996, Pages 205-211

  Kimura, Mikio ^a   Kuno Sakai, Harumi ^a   Yamazaki, Shudo ^b   Yamada, Akio ^b   Hishiyama, Michiko ^b   Kamiya, Hitoshi ^c   Ueda, Koji ^d   Murase, Toshiro ^e   Hirayama, Munehiro ^f   Oya, Akira ^b   Nozaki, Sadahiko ^g   Murata, Ryosuke ^b  

^a TOKAI UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c MIE NATIONAL HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e World Medical Association   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g NIHON UNIVERSITY   (Japan)

Author keywords

Aseptic meningitis; Convulsion; MMR vaccine; Urabe Am9 mumps vaccines

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS VACCINE; MEASLES VACCINE; MUMPS VACCINE; RUBELLA VACCINE;

ANIMAL CELL; ARTICLE; ASEPTIC MENINGITIS; CHILD; CLINICAL TRIAL; CONVULSION; DRUG MANUFACTURE; DRUG SURVEILLANCE PROGRAM; FEVER; HUMAN; IMMUNIZATION; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MONOLAYER CULTURE; MUMPS; MUMPS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; VERO CELL; VIRUS STRAIN; VOMITING;

CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; INFANT; JAPAN; MALE; MEASLES VACCINE; MEASLES-MUMPS-RUBELLA VACCINE; MENINGITIS, ASEPTIC; MUMPS VACCINE; PAROTITIS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK; RUBELLA VACCINE; SEIZURES; VACCINES, COMBINED;

EID: 8944248814     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.1996.tb03471.x     Document Type: Article

References (12)

1. Kuno-Sakai H., Kimura M. Measles Mumps Rubella (MMR) vaccine in Japan. Acta Paediatr. Jpn. 1988, 30: 167–74.
2. Kuno-Sakai H., Kimura M. MMR vaccines. Clin. Virol. 1991; 19(3): 1–11 (in Jpn.).
3. Yamada A., Takeuchi K., Tanabayashi K., Hishiyama M., Takahashi Y., Sugiura A. Differentiation of the mumps vaccine strains from the wild viruses by the nucleotide sequences of the P gene. Vaccine 1990; 8: 553–7.
4. Katayama K., Oya A., Tanabayashi K. et al. Differentiation of mumps vaccine strains from wild viruses by single-strand conformation polymorphism of the P gene. Vaccine 1993; 11: 621–3.
5. Sawada H., Yano S., Oka S., Togashi T. Transmission of Urabe mumps vaccine between siblings. Lancet 1993; 342: 371.
6. Umino Y., Saito S., Fukuda A., Hishiyama M., Sugiura A. Improvement in potency assay of measles-mumps-rubella trivalent vaccine: interference between components and measures for its elimination. J. Virol. Methods 1990; 27: 159–168.
7. Maruyama H., Tomizawa I. Governmental policies on occurrence of aseptic meningitis after MMR vaccination. Clin. Virol. 1994; 2(1): 77–82 (in Jpn.).
8. Nalin D. Evaluating mumps vaccine. [letter] Lancet 1992; 339: 305.
9. Fescharek R., Quast U., Maass G., Merkle W., Schwarz S. Measles mumps vaccination in the FRG: An empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects. Vaccine 1990; 8: 446–56.
10. Maguire HC, Begg NT, Handford SG. Meningo-encephalitis associated with MMR vaccine. Communic. Dis. Report 1991; 1(6): 60–1.
11. Miller E., Goldacre M., Pughs S. et al. Risk of aseptic meningitis after measles, mumps and rubella vaccine in UK children. Lancet 1993; 341: 979–82.
12. Colville A., Pughs S. Mumps meningitis and measles, mumps, and rubella vaccine. Lancet 1992; 340: 786.